Mendel Goldfinger is an Oncology physician affiliated with Albert Einstein College of Medicine. OpenAlex indexes 212 publications with 1,882 citations (h-index 15); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
506 6th St
Brooklyn, NY 112153609
Telephone
646-221-7710Registry record last updated 17 Mar 2018.
Clinical trials
- FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
Sponsor: Montefiore Medical Center
- A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
Sponsor: Treebough Therapies
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year202514 payments
- ABBVIE INC.Program year20257 payments
- GlaxoSmithKline, LLC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
45%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor24.5%Valacyclovir100%Part D≥26 patientsShort-acting sulfonamides11.2%Sulfamethoxazole-Trimethoprim100%Part D≥19 patients+ 1 more class in this area
Cardiovascular
16.1%Calcium channel blocker6%Amlodipine Besylate100%Part D<11 patientsBeta blocker5.6%Propranolol Hcl Er100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
14.5%BCL-2 Inhibitor9.6%Venclexta100%Part D<11 patientsKinase inhibitor4.8%Imbruvica100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Lipton, MD
Albert Einstein College of Medicine
Marina Konopleva, MD, PhD
Albert Einstein College of Medicine
Solomon Moshe, MD
Albert Einstein College of Medicine
Shlomo Shinnar, MD, PhD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”